Physician profile
Shiree Sauer
NPI 1932172996
$3,029.94
in general payments reported to CMS, 2019-2025
26 companies · $704 in 2025
The $704 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $163 · 2021: $438 · 2022: $337 · 2023: $536 · 2024: $646 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $423.02 | 2022-2025 | Azstarys |
| Tris Pharma INC | $324.86 | 2019-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $317.83 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Merck Sharp & Dohme LLC | $280.14 | 2019-2025 | Gardasil 9, Vaxneuvance, Enflonsia |
| Supernus Pharmaceuticals, INC. | $242.70 | 2023-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $161.54 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $139.69 | 2024 | Ycanth |
| Pfizer INC. | $131.74 | 2021-2025 | |
| Neos Therapeutics, LP | $126.55 | 2019-2024 | Cotempla Xr-Odt |
| Ars Pharmaceuticals Operations, INC. | $124.99 | 2025 | Neffy |
| Sanofi Pasteur INC. | $116.35 | 2021-2024 | |
| Cranial Technologies, INC | $114.63 | 2021-2024 | Doc Band |
| Kaleo, INC. | $107.59 | 2019-2022 | |
| Genzyme Corporation | $93.80 | 2025 | |
| Acadia Pharmaceuticals INC | $50.34 | 2025 | Daybue |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $46.68 | 2025 | Jornay Pm |
| Lnhc, INC | $46.41 | 2025 | Zelsuvmi |
| Ironshore Pharmaceuticals INC. | $42.88 | 2024 | |
| Adlon Therapeutics L.P. | $30.26 | 2020-2021 | |
| Cipher Pharmaceuticals US LLC | $22.18 | 2025 | Spinosad, Natroba |
| Neurelis, INC. | $18.50 | 2021 | |
| Hologic Sales and Service, LLC | $18.16 | 2023 | Aptima |
| Vertical Pharmaceuticals, LLC | $12.79 | 2019 | |
| Masimo Corporation | $12.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.22 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shiree Sauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.